APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Biologics and Biosimilars Industry Growth and Trends Forecast to 2032

Report ID 173970720126 December 2025124 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

According to APO Research, the global Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Biologics and Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biologics and Biosimilars market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biologics and Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biologics and Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Biologics and Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biologics and Biosimilars Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Pfizer

AbbVie

United Laboratory

Tonghua Dongbao

Sobi

Novo Nordisk

Kanghong Pharma

Innovent Biologics

Gan&Lee

Eli Lilly

Changchun High Tech

Celltrion

Biogen

Amgen

3SBIO

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Biologics and Biosimilars companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Biologics and Biosimilars Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Biologics and Biosimilars Market Share by Region (2021-2026) Table 4. Global Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Biologics and Biosimilars Market Share by Region (2027-2032) Table 6. Global Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Biologics and Biosimilars Market Size Share by Type (2021-2026) Table 9. Global Biologics and Biosimilars Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Biologics and Biosimilars Market Size Share Forecasted by Type (2027-2032) Table 11. North America Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Biologics and Biosimilars Market Size Share by Application (2021-2026) Table 24. Global Biologics and Biosimilars Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Biologics and Biosimilars Market Size Share Forecasted by Application (2027-2032) Table 26. North America Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Biologics and Biosimilars Industry Trends Table 37. Biologics and Biosimilars Industry Drivers Table 38. Biologics and Biosimilars Industry Opportunities and Challenges Table 39. Biologics and Biosimilars Industry Restraints Table 40. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 42. Global Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Biologics and Biosimilars Key Company Headquarters & Area Served Table 44. Global Biologics and Biosimilars Company, Product Type & Application Table 45. Global Biologics and Biosimilars Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sanofi Biologics and Biosimilars Product Portfolio Table 52. Sanofi Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis Biologics and Biosimilars Product Portfolio Table 62. Novartis Recent Development Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Merck Biologics and Biosimilars Product Portfolio Table 67. Merck Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Roche Biologics and Biosimilars Product Portfolio Table 72. Roche Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Pfizer Biologics and Biosimilars Product Portfolio Table 77. Pfizer Recent Development Table 78. AbbVie Company Information Table 79. AbbVie Business Overview Table 80. AbbVie Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. AbbVie Biologics and Biosimilars Product Portfolio Table 82. AbbVie Recent Development Table 83. United Laboratory Company Information Table 84. United Laboratory Business Overview Table 85. United Laboratory Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. United Laboratory Biologics and Biosimilars Product Portfolio Table 87. United Laboratory Recent Development Table 88. Tonghua Dongbao Company Information Table 89. Tonghua Dongbao Business Overview Table 90. Tonghua Dongbao Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Tonghua Dongbao Biologics and Biosimilars Product Portfolio Table 92. Tonghua Dongbao Recent Development Table 93. Sobi Company Information Table 94. Sobi Business Overview Table 95. Sobi Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Sobi Biologics and Biosimilars Product Portfolio Table 97. Sobi Recent Development Table 98. Novo Nordisk Company Information Table 99. Novo Nordisk Business Overview Table 100. Novo Nordisk Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 102. Novo Nordisk Recent Development Table 103. Kanghong Pharma Company Information Table 104. Kanghong Pharma Business Overview Table 105. Kanghong Pharma Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Kanghong Pharma Biologics and Biosimilars Product Portfolio Table 107. Kanghong Pharma Recent Development Table 108. Innovent Biologics Company Information Table 109. Innovent Biologics Business Overview Table 110. Innovent Biologics Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Innovent Biologics Biologics and Biosimilars Product Portfolio Table 112. Innovent Biologics Recent Development Table 113. Gan&Lee Company Information Table 114. Gan&Lee Business Overview Table 115. Gan&Lee Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Gan&Lee Biologics and Biosimilars Product Portfolio Table 117. Gan&Lee Recent Development Table 118. Eli Lilly Company Information Table 119. Eli Lilly Business Overview Table 120. Eli Lilly Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Eli Lilly Biologics and Biosimilars Product Portfolio Table 122. Eli Lilly Recent Development Table 123. Changchun High Tech Company Information Table 124. Changchun High Tech Business Overview Table 125. Changchun High Tech Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 127. Changchun High Tech Recent Development Table 128. Celltrion Company Information Table 129. Celltrion Business Overview Table 130. Celltrion Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Celltrion Biologics and Biosimilars Product Portfolio Table 132. Celltrion Recent Development Table 133. Biogen Company Information Table 134. Biogen Business Overview Table 135. Biogen Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Biogen Biologics and Biosimilars Product Portfolio Table 137. Biogen Recent Development Table 138. Amgen Company Information Table 139. Amgen Business Overview Table 140. Amgen Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Amgen Biologics and Biosimilars Product Portfolio Table 142. Amgen Recent Development Table 143. 3SBIO Company Information Table 144. 3SBIO Business Overview Table 145. 3SBIO Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. 3SBIO Biologics and Biosimilars Product Portfolio Table 147. 3SBIO Recent Development Table 148. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Biologics and Biosimilars Market Share by Country (2021-2026) Table 151. North America Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 153. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Biologics and Biosimilars Market Share by Country (2021-2026) Table 156. Europe Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Biologics and Biosimilars Market Share by Country (2021-2026) Table 161. Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 163. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Biologics and Biosimilars Market Share by Country (2021-2026) Table 166. Latin America Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Biologics and Biosimilars Market Share by Country (2021-2026) Table 171. Middle East & Africa Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Biologics and Biosimilars Product Image Figure 3. Global Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 5. Global Biologics and Biosimilars Market Share by Region: 2025 VS 2032 Figure 6. Global Biologics and Biosimilars Market Share by Region (2021-2032) Figure 7. North America Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Monoclonal Antibodies Image Figure 13. Global Monoclonal Antibodies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Interferon Image Figure 15. Global Interferon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Insulin Image Figure 17. Global Insulin Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Vaccines Image Figure 19. Global Vaccines Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Biologics and Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Biologics and Biosimilars Market Share by Type 2025 VS 2032 Figure 24. North America Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 25. Europe Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 27. Latin America Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 29. Hospital Image Figure 30. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Retail Pharmacy Image Figure 32. Global Retail Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Other Image Figure 34. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Biologics and Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Biologics and Biosimilars Market Share by Application 2025 VS 2032 Figure 37. North America Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 38. Europe Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 40. Latin America Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Biologics and Biosimilars Market Share by Country (2021-2032) Figure 47. Europe Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Biologics and Biosimilars Market Share by Country (2021-2032) Figure 50. Asia-Pacific Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Biologics and Biosimilars Market Share by Country (2021-2032) Figure 53. Latin America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Biologics and Biosimilars Market Share by Country (2021-2032) Figure 56. Middle East & Africa Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Biologics and Biosimilars Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • AbbVie
  • United Laboratory
  • Tonghua Dongbao
  • Sobi
  • Novo Nordisk
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Eli Lilly
  • Changchun High Tech
  • Celltrion
  • Biogen
  • Amgen
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Biologics and Biosimilars Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Biologics and Biosimilars Market Size by Region (2021-2032)
  5. 1.4.1 Global Biologics and Biosimilars Market Size by Region (2021-2026)
  6. 1.4.2 Global Biologics and Biosimilars Market Size by Region (2027-2032)
  7. 1.5 Key Regions Biologics and Biosimilars Market Size (2021-2032)
  8. 1.5.1 North America Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Biologics and Biosimilars Market Size Growth Rate (2021-2032)
2 Biologics and Biosimilars Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Monoclonal Antibodies
  3. 2.1.2 Interferon
  4. 2.1.3 Insulin
  5. 2.1.4 Vaccines
  6. 2.1.5 Others
  7. 2.2 Global Biologics and Biosimilars Market Size by Type
  8. 2.2.1 Global Biologics and Biosimilars Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Biologics and Biosimilars Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Biologics and Biosimilars Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Biologics and Biosimilars Market Size by Regions
  12. 2.3.1 North America Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
3 Biologics and Biosimilars Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Retail Pharmacy
  4. 3.1.3 Other
  5. 3.2 Global Biologics and Biosimilars Market Size by Application
  6. 3.2.1 Global Biologics and Biosimilars Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Biologics and Biosimilars Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Biologics and Biosimilars Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Biologics and Biosimilars Market Size by Regions
  10. 3.3.1 North America Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Biologics and Biosimilars Industry Trends
  2. 4.2 Biologics and Biosimilars Industry Drivers
  3. 4.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 4.4 Biologics and Biosimilars Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Biologics and Biosimilars Revenue (2021-2026)
  2. 5.2 Global Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Biologics and Biosimilars Key Company Headquarters & Area Served
  4. 5.4 Global Biologics and Biosimilars Company, Product Type & Application
  5. 5.5 Global Biologics and Biosimilars Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Biologics and Biosimilars Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Biologics and Biosimilars Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Merck Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Roche Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 AbbVie
  38. 6.7.1 AbbVie Company Information
  39. 6.7.2 AbbVie Business Overview
  40. 6.7.3 AbbVie Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 AbbVie Biologics and Biosimilars Product Portfolio
  42. 6.7.5 AbbVie Recent Developments
  43. 6.8 United Laboratory
  44. 6.8.1 United Laboratory Company Information
  45. 6.8.2 United Laboratory Business Overview
  46. 6.8.3 United Laboratory Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
  48. 6.8.5 United Laboratory Recent Developments
  49. 6.9 Tonghua Dongbao
  50. 6.9.1 Tonghua Dongbao Company Information
  51. 6.9.2 Tonghua Dongbao Business Overview
  52. 6.9.3 Tonghua Dongbao Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Tonghua Dongbao Recent Developments
  55. 6.10 Sobi
  56. 6.10.1 Sobi Company Information
  57. 6.10.2 Sobi Business Overview
  58. 6.10.3 Sobi Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Sobi Biologics and Biosimilars Product Portfolio
  60. 6.10.5 Sobi Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Kanghong Pharma
  68. 6.12.1 Kanghong Pharma Company Information
  69. 6.12.2 Kanghong Pharma Business Overview
  70. 6.12.3 Kanghong Pharma Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Kanghong Pharma Recent Developments
  73. 6.13 Innovent Biologics
  74. 6.13.1 Innovent Biologics Company Information
  75. 6.13.2 Innovent Biologics Business Overview
  76. 6.13.3 Innovent Biologics Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
  78. 6.13.5 Innovent Biologics Recent Developments
  79. 6.14 Gan&Lee
  80. 6.14.1 Gan&Lee Company Information
  81. 6.14.2 Gan&Lee Business Overview
  82. 6.14.3 Gan&Lee Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
  84. 6.14.5 Gan&Lee Recent Developments
  85. 6.15 Eli Lilly
  86. 6.15.1 Eli Lilly Company Information
  87. 6.15.2 Eli Lilly Business Overview
  88. 6.15.3 Eli Lilly Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  90. 6.15.5 Eli Lilly Recent Developments
  91. 6.16 Changchun High Tech
  92. 6.16.1 Changchun High Tech Company Information
  93. 6.16.2 Changchun High Tech Business Overview
  94. 6.16.3 Changchun High Tech Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  96. 6.16.5 Changchun High Tech Recent Developments
  97. 6.17 Celltrion
  98. 6.17.1 Celltrion Company Information
  99. 6.17.2 Celltrion Business Overview
  100. 6.17.3 Celltrion Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Celltrion Biologics and Biosimilars Product Portfolio
  102. 6.17.5 Celltrion Recent Developments
  103. 6.18 Biogen
  104. 6.18.1 Biogen Company Information
  105. 6.18.2 Biogen Business Overview
  106. 6.18.3 Biogen Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Biogen Biologics and Biosimilars Product Portfolio
  108. 6.18.5 Biogen Recent Developments
  109. 6.19 Amgen
  110. 6.19.1 Amgen Company Information
  111. 6.19.2 Amgen Business Overview
  112. 6.19.3 Amgen Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Amgen Biologics and Biosimilars Product Portfolio
  114. 6.19.5 Amgen Recent Developments
  115. 6.20 3SBIO
  116. 6.20.1 3SBIO Company Information
  117. 6.20.2 3SBIO Business Overview
  118. 6.20.3 3SBIO Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 3SBIO Biologics and Biosimilars Product Portfolio
  120. 6.20.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 7.3 North America Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 8.3 Europe Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 10.3 South America Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst